Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
17%
Ph early_phase_1
1
17%
Ph not_applicable
1
17%
Ph phase_3
1
17%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(2)

Detailed Status

Completed2
Not yet recruiting2
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
N/A1 (25.0%)

Trials by Status

active_not_recruiting117%
completed233%
not_yet_recruiting233%
recruiting117%

Recent Activity

2 active trials
Showing 5 of 6
recruitingphase_2

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428
not_yet_recruitingphase_3

Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention

NCT07228663
not_yet_recruitingearly_phase_1

DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial

NCT07011095
active_not_recruitingnot_applicable

OPTIMAS: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial

NCT03759938
completed

An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres

NCT02470767
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05498428Phase 2

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Recruiting
NCT07228663Phase 3

Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention

Not Yet Recruiting
NCT07011095Early Phase 1

DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial

Not Yet Recruiting
NCT03759938Not Applicable

OPTIMAS: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial

Active Not Recruiting
NCT02470767

An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres

Completed
NCT02559232

An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6